About

About IMBdx, Inc. About IMBdx IMBdx is a liquid biopsy-focused precision oncology company that develops minimally invasive, comprehensive genomic profiling (CGP) assays. IMBdx Inc.’s AlphaLiquid® platform offers ctDNA-based precision diagnostics solutions across the full continuum of cancer care, from therapy selection (AlphaLiquid®100) to recurrence and minimal residual disease (MRD) monitoring (CancerDetect™), AND multi-cancer early detection (CancerFind™). Our proprietary technology detects and analyzes trace amounts of tumor-derived DNA in body fluids using AI-driven bioinformatic algorithms. IMBdx is the dominant liquid biopsy diagnostics provider in South Korea and a growing liquid biopsy company globally. We also offer customized solutions for biopharma companies to assist in biomarker validation and companion diagnostics development. IMBdx Inc.’s AlphaLiquid® platform offers ctDNA-based precision diagnostics solutions across the full continuum of cancer care, from therapy selection (AlphaLiquid®100) to recurrence and minimal residual disease (MRD) monitoring (CancerDetect™), and multi-cancer early detection (CancerFind™) using liquid biopsy-based NGS technology. IMBdx is a liquid biopsy-focused precision oncology company that develops minimally invasive, comprehensive genomic profiling (CGP) assays. IMBdx Inc.’s AlphaLiquid® platform offers ctDNA-based precision diagnostics solutions across the full continuum of cancer care, from therapy selection (AlphaLiquid®100) to recurrence and minimal residual disease (MRD) monitoring (CancerDetect™), AND multi-cancer early detection (CancerFind™). Our proprietary technology detects and analyzes trace amounts of tumor-derived DNA in body fluids using AI-driven bioinformatic algorithms. IMBdx is the dominant liquid biopsy diagnostics provider in South Korea and a growing liquid biopsy company globally. We also offer customized solutions for biopharma companies to assist in biomarker validation and companion diagnostics development. IMBdx (In My Blood diagnostics) is a precision oncology company specializing in liquid biopsy technologies. We empower physicians and patients worldwide by providing advanced, non-invasive solutions for cancer detection, monitoring, and treatment guidance. Using a single blood draw, we analyze a broad spectrum of tumor-derived genetic alterations to offer actionable insights at a reasonable cost. Our in-house laboratory and proprietary analytical platforms are optimized for ultra-sensitive mutation detection. By integrating clinical big data with artificial intelligence, we support physicians in predicting treatment response and patient outcomes. Liquid biopsy is a minimally invasive method that detects circulating tumor DNA (ctDNA) in body fluids such as blood, cerebrospinal fluid, or pleural effusion. It offers a safer and simpler alternative to traditional tissue biopsy, enabling real-time monitoring of disease progression, therapy response, and early recurrence. 1. AlphaLiquid®100 Ultrasensitive ctDNA Liquid Biopsy Platform for Comprehensive Genomic Profiling AlphaLiquid100 provides comprehensive genomic profiling for patients with advanced solid tumors. It assesses alterations across 118 cancer-related genes, including 15 HRR genes and 10 gene fusions, to support personalized treatment planning, targeted therapy selection, and response monitoring. 2. CancerDetect™ Tumor-informed, Hybrid Capture-based ctDNA Assay for MRD Detection CancerDetect is an NGS-based, patient-customized assay designed for the detection of minimal residual disease (MRD) and recurrence surveillance in stage I–III solid tumors. It utilizes up to 500 tumor-informed and therapeutic targets, offering highly sensitive detection with a lead time advantage over radiological imaging. 3. CancerFind™ Accurate Multi-Cancer Early Detection with a Single Blood Test CancerFind enables early detection of eight major cancers—colon, stomach, liver, pancreatic, lung, breast, ovarian, and prostate—with one blood sample. By analyzing ctDNA with advanced technology, it not only detects cancer presence but also identifies the most likely tissue of origin, supporting early intervention and informed clinical decisions.